> top > docs > PubMed:11299793 > annotations

PubMed:11299793 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 18-48 gene:2247 denotes basic fibroblast growth factor
T1 91-115 disease:C0007112 denotes prostatic adenocarcinoma
T2 53-87 gene:7422 denotes vascular endothelial growth factor
T3 91-115 disease:C0007112 denotes prostatic adenocarcinoma
T4 367-403 gene:2247 denotes basic fibroblast growth factor (bFGF
T5 535-559 disease:C0007112 denotes prostatic adenocarcinoma
T6 445-449 gene:7422 denotes VEGF
T7 535-559 disease:C0007112 denotes prostatic adenocarcinoma
T8 409-443 gene:7422 denotes vascular endothelial growth factor
T9 535-559 disease:C0007112 denotes prostatic adenocarcinoma
T10 1002-1006 gene:7422 denotes VEGF
T11 1036-1050 disease:C0001418 denotes adenocarcinoma
R1 T0 T1 associated_with basic fibroblast growth factor,prostatic adenocarcinoma
R2 T2 T3 associated_with vascular endothelial growth factor,prostatic adenocarcinoma
R3 T4 T5 associated_with basic fibroblast growth factor (bFGF,prostatic adenocarcinoma
R4 T6 T7 associated_with VEGF,prostatic adenocarcinoma
R5 T8 T9 associated_with vascular endothelial growth factor,prostatic adenocarcinoma
R6 T10 T11 associated_with VEGF,adenocarcinoma

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
11299793-6#84#88#gene7422 1142-1146 gene7422 denotes VEGF
11299793-6#125#139#diseaseC0001418 1183-1197 diseaseC0001418 denotes adenocarcinoma
84#88#gene7422125#139#diseaseC0001418 11299793-6#84#88#gene7422 11299793-6#125#139#diseaseC0001418 associated_with VEGF,adenocarcinoma

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 166-576 BACKGROUND denotes Neovascularization associated with tumor invasion and metastasis may be stimulated by factors which are released from tumor cells, tumor-associated inflammatory cells or extracellular matrix. Although basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) have been characterized as promoters of angiogenesis, their precise localization in prostatic adenocarcinoma remains unclear.
T2 600-900 METHODS denotes In this study, the immunohistochemical expression of the growth factors and their receptors were studied using paraffin-embedded archival tissues before and after neoadjuvant hormonal therapy. The mRNA expression of the growth factors was also examined using an in situ hybridization (ISH) technique.
T3 910-1701 RESULTS denotes The ISH study demonstrated that bFGF mRNA was present only in the stromal cells whilst that VEGF mRNA was present only in the adenocarcinoma cells. In contrast, the immunohistochemical study showed that bFGF, FGF receptor, VEGF and VEGF receptor proteins were expressed in adenocarcinoma cells and in endothelial cells. We also observed that microvessel density in prostatic adenocarcinoma was correlated with the degree of the expression of growth factors in the cases without neoadjuvant hormonal therapy. Additionally, the expression of those receptor proteins were much frequently identified in the cases with neoadjuvant hormonal therapy than those without it, while virtually no change in the expression of ligands was observed between the cases without and with neoadjuvant therapies.
T4 1715-1961 CONCLUSIONS denotes In prostatic adenocarcinoma, bFGF and VEGF may correlate with neovascularization through each characteristic pathway. In addition, we assumed that neoadjuvant hormonal therapy may have minimal inhibitory effects on bFGF, VEGF and their receptors.